Who
Tommy G. Thompson
Director
Company insider
Files Form 4 as: Director, United Therapeutics; Chairman, TherapeuticsMD; Director, Healthpeak Properties; Director, Physicians Realty Trust; Director, Scilex Holding; Director, Centene; Director, Tyme Technologies; Director, Bard C R Inc /nj/.
In numbers
- Trades disclosed
- 570
- Buys
- 38
- Sells
- 54
- Bought
- $1.9M
- Sold
- $19.4M
- Companies
- 14
- Companies where not an officer
- 13
- First trade
- 30 Sep 2005
- Last trade
- 22 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —380 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,190 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —380 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,190 at $0.00 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $204K2,000 at $101.80 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $148K275 at $537.62 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $762K1,414 at $539.25 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $168K311 at $540.18 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $204K2,000 at $101.80 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $148K275 at $537.62 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $762K1,414 at $539.25 | filing |
| 26 Mar 2026filed 26 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $168K311 at $540.18 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $204K2,000 at $101.80 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $979K2,000 at $489.42 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $204K2,000 at $101.80 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $979K2,000 at $489.42 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Share Repurchase Plan Announced by United Therapeutics (NASDAQ:UTHR) Board of DirectorsUTHR · tickerreport.com · 23 Oct 2026United Therapeutics (NASDAQ:UTHR) Price Target Raised to $725.00UTHR · dailypolitical.com · 22 Oct 2026Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)UTHR · dailypolitical.com · 18 Oct 2026TherapeuticsMD (NASDAQ:TXMD) vs. Addex Therapeutics (NASDAQ:ADXN) Head to Head ComparisonTXMD · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Tommy G. Thompson; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.